Trial · NCT02641730
Participant flow45
How many started, completed or left each group, period by period.
1 to 20 of 45
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Placebo Controlled Period (Week 0 - 16) | STARTED | Placebo | 53 | |
| Placebo Controlled Period (Week 0 - 16) | STARTED | Placebo Then Guselkumab 100 mg | 0 | |
| Placebo Controlled Period (Week 0 - 16) | STARTED | Placebo Then Guselkumab 200 mg | 0 | |
| Placebo Controlled Period (Week 0 - 16) | STARTED | Guselkumab 100 mg | 54 | |
| Placebo Controlled Period (Week 0 - 16) | STARTED | Guselkumab 200 mg | 52 | |
| Placebo Controlled Period (Week 0 - 16) | COMPLETED | Placebo | 51 | |
| Placebo Controlled Period (Week 0 - 16) | COMPLETED | Placebo Then Guselkumab 100 mg | 0 | |
| Placebo Controlled Period (Week 0 - 16) | COMPLETED | Placebo Then Guselkumab 200 mg | 0 | |
| Placebo Controlled Period (Week 0 - 16) | COMPLETED | Guselkumab 100 mg | 53 | |
| Placebo Controlled Period (Week 0 - 16) | COMPLETED | Guselkumab 200 mg | 50 | |
| Placebo Controlled Period (Week 0 - 16) | NOT COMPLETED | Placebo | 2 | |
| Placebo Controlled Period (Week 0 - 16) | NOT COMPLETED | Placebo Then Guselkumab 100 mg | 0 | |
| Placebo Controlled Period (Week 0 - 16) | NOT COMPLETED | Placebo Then Guselkumab 200 mg | 0 | |
| Placebo Controlled Period (Week 0 - 16) | NOT COMPLETED | Guselkumab 100 mg | 1 | |
| Placebo Controlled Period (Week 0 - 16) | NOT COMPLETED | Guselkumab 200 mg | 2 | |
| After Controlled Period (Week 16 - 52) | STARTED | Placebo | 0 | |
| After Controlled Period (Week 16 - 52) | STARTED | Placebo Then Guselkumab 100 mg | 25 | |
| After Controlled Period (Week 16 - 52) | STARTED | Placebo Then Guselkumab 200 mg | 26 | |
| After Controlled Period (Week 16 - 52) | STARTED | Guselkumab 100 mg | 53 | |
| After Controlled Period (Week 16 - 52) | STARTED | Guselkumab 200 mg | 50 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02641730/flow